You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTenoxicam
Accession NumberDB00469  (APRD00011)
TypeSmall Molecule
GroupsApproved
DescriptionTenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Structure
Thumb
Synonyms
Tenoxicam
Ténoxicam
Tenoxicamum
External Identifiers
  • RO 12-0068
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mobiflex Tab 20mgtablet20 mgoralHoffmann La Roche Limited1991-12-312001-07-19Canada
Novo-tenoxicam Tab 20mgtablet20 mgoralNovopharm Limited1997-06-052005-08-10Canada
Nu-tenoxicamtablet20 mgoralNu Pharm IncNot applicableNot applicableCanada
Tenoxicam Tabletstablet20 mgoralAa Pharma Inc1997-02-21Not applicableCanada
Tenoxicam-20tablet20 mgoralPro Doc Limitee1998-11-242009-07-23Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MobiflexRoche
OctiveranRafarm
OxicamACI
OxytelCoup
PalitenoxPharmathen
TenorixOrion
TenxilUnison
TilcotilMeda
TilflamDexa Medica
TilkoKoçak
TilnoxcamT. O. Chemicals
TiloxicanHexal
TobitilRanbaxy
TonoxUtopian
ToscacalmGenepharm
VelasorVocate
VienoksToprak
VoirVelka
XicotilAristopharma
ZibelantChrispa
ZikaralSanovel
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIZ1R9N0A399
CAS number59804-37-4
WeightAverage: 337.37
Monoisotopic: 337.019098194
Chemical FormulaC13H11N3O4S2
InChI KeyLZNWYQJJBLGYLT-UHFFFAOYSA-N
InChI
InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
IUPAC Name
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶-thieno[2,3-e][1,2]thiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Thienothiazine
  • N-arylamide
  • Ortho-thiazine
  • Pyridine
  • Imidolactam
  • Organosulfonic acid amide
  • Heteroaromatic compound
  • Organic sulfonic acid or derivatives
  • Organosulfonic acid or derivatives
  • Vinylogous acid
  • Thiophene
  • Carboxamide group
  • Secondary carboxylic acid amide
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organooxygen compound
  • Organonitrogen compound
  • Organopnictogen compound
  • Carbonyl group
  • Organic nitrogen compound
  • Organic oxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.
PharmacodynamicsTenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Mechanism of actionThe antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.
Related Articles
AbsorptionOral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%).
Volume of distributionNot Available
Protein binding99%
Metabolism

Tenoxicam is metabolized in the liver to several pharmacologically inactive metabolites (mainly 5'-hydroxy-tenoxicam).

SubstrateEnzymesProduct
Tenoxicam
5'-HydroxytenoxicamDetails
Route of eliminationNot Available
Half life72 hours (range 59 to 74 hours)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tenoxicam Action PathwayDrug actionSMP00706
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier-0.9455
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5536
P-glycoprotein inhibitor INon-inhibitor0.7976
P-glycoprotein inhibitor IINon-inhibitor0.8024
Renal organic cation transporterNon-inhibitor0.9191
CYP450 2C9 substrateSubstrate0.6922
CYP450 2D6 substrateNon-substrate0.8896
CYP450 3A4 substrateNon-substrate0.7105
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.7661
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8966
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9057
Ames testNon AMES toxic0.8655
CarcinogenicityNon-carcinogens0.7271
BiodegradationNot ready biodegradable0.936
Rat acute toxicity3.4010 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9633
hERG inhibition (predictor II)Non-inhibitor0.8785
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral20 mg
Prices
Unit descriptionCostUnit
Apo-Tenoxicam 20 mg Tablet1.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point211 dec °CPhysProp
water solubility14.1 mg/LNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.257 mg/mLALOGPS
logP2.42ALOGPS
logP-0.12ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)2.21ChemAxon
pKa (Strongest Basic)4.26ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity83.93 m3·mol-1ChemAxon
Polarizability31.96 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AC02
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.1 KB)
Interactions
Drug Interactions
Drug
AbciximabTenoxicam may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Tenoxicam can be decreased when combined with Abiraterone.
AcebutololTenoxicam may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Aceclofenac.
AcenocoumarolTenoxicam may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tenoxicam.
Alendronic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.
AliskirenTenoxicam may decrease the antihypertensive activities of Aliskiren.
AlprenololTenoxicam may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tenoxicam.
AmikacinTenoxicam may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideTenoxicam may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Tenoxicam can be decreased when combined with Amiodarone.
AncrodTenoxicam may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Antipyrine.
Antithrombin III humanTenoxicam may increase the anticoagulant activities of Antithrombin III human.
ApixabanTenoxicam may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Apremilast.
AprepitantThe metabolism of Tenoxicam can be increased when combined with Aprepitant.
ArdeparinTenoxicam may increase the anticoagulant activities of Ardeparin.
ArgatrobanTenoxicam may increase the anticoagulant activities of Argatroban.
ArotinololTenoxicam may decrease the antihypertensive activities of Arotinolol.
AtenololTenoxicam may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tenoxicam.
BalsalazideTenoxicam may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tenoxicam.
BecaplerminTenoxicam may increase the anticoagulant activities of Becaplermin.
BefunololTenoxicam may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tenoxicam.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tenoxicam.
BenoxaprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Benoxaprofen.
BetaxololTenoxicam may decrease the antihypertensive activities of Betaxolol.
BevantololTenoxicam may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tenoxicam.
BisoprololTenoxicam may decrease the antihypertensive activities of Bisoprolol.
BivalirudinTenoxicam may increase the anticoagulant activities of Bivalirudin.
BopindololTenoxicam may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Bromfenac.
BufuralolTenoxicam may decrease the antihypertensive activities of Bufuralol.
BumetanideTenoxicam may decrease the diuretic activities of Bumetanide.
BupranololTenoxicam may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tenoxicam.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tenoxicam.
CapecitabineThe metabolism of Tenoxicam can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tenoxicam.
CarbamazepineThe metabolism of Tenoxicam can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tenoxicam.
CarprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Carprofen.
CarteololTenoxicam may decrease the antihypertensive activities of Carteolol.
CarvedilolTenoxicam may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Celecoxib.
CeliprololTenoxicam may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Tenoxicam can be increased when it is combined with Ceritinib.
CertoparinTenoxicam may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenoxicam.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tenoxicam.
CholecalciferolThe metabolism of Tenoxicam can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tenoxicam.
Citric AcidTenoxicam may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tenoxicam.
ClotrimazoleThe metabolism of Tenoxicam can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineTenoxicam may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Tenoxicam can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with D-Limonene.
Dabigatran etexilateTenoxicam may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Tenoxicam can be decreased when it is combined with Dabrafenib.
DalteparinTenoxicam may increase the anticoagulant activities of Dalteparin.
DanaparoidTenoxicam may increase the anticoagulant activities of Danaparoid.
DaunorubicinTenoxicam may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Deferasirox.
DelavirdineThe metabolism of Tenoxicam can be decreased when combined with Delavirdine.
DesirudinTenoxicam may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tenoxicam.
DextranTenoxicam may increase the anticoagulant activities of Dextran.
Dextran 40Tenoxicam may increase the anticoagulant activities of Dextran 40.
Dextran 70Tenoxicam may increase the anticoagulant activities of Dextran 70.
Dextran 75Tenoxicam may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Diclofenac.
DicoumarolTenoxicam may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tenoxicam.
DihydrostreptomycinTenoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tenoxicam.
DoxorubicinTenoxicam may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneTenoxicam may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Droxicam.
Edetic AcidTenoxicam may increase the anticoagulant activities of Edetic Acid.
EdoxabanTenoxicam may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Tenoxicam can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tenoxicam.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tenoxicam.
EnoxaparinTenoxicam may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Epirizole.
EpirubicinTenoxicam may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneTenoxicam may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tenoxicam.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tenoxicam.
EsmololTenoxicam may decrease the antihypertensive activities of Esmolol.
Etacrynic acidTenoxicam may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tenoxicam.
Ethyl biscoumacetateTenoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etoricoxib.
EtravirineThe metabolism of Tenoxicam can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Tenoxicam is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tenoxicam.
FloxuridineThe metabolism of Tenoxicam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Tenoxicam can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flunixin.
FluorouracilThe metabolism of Tenoxicam can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flurbiprofen.
FluvastatinThe metabolism of Tenoxicam can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Tenoxicam can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tenoxicam.
Fondaparinux sodiumTenoxicam may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tenoxicam.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tenoxicam.
FosphenytoinThe metabolism of Tenoxicam can be increased when combined with Fosphenytoin.
FramycetinTenoxicam may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideTenoxicam may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tenoxicam.
GemfibrozilThe metabolism of Tenoxicam can be decreased when combined with Gemfibrozil.
GentamicinTenoxicam may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Haloperidol.
HeparinTenoxicam may increase the anticoagulant activities of Heparin.
HirulogTenoxicam may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Tenoxicam is combined with HMPL-004.
HydralazineTenoxicam may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tenoxicam.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tenoxicam.
Hygromycin BTenoxicam may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Icatibant.
IdarubicinTenoxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tenoxicam.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tenoxicam.
IndenololTenoxicam may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Tenoxicam can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenoxicam.
IndoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tenoxicam.
IsoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Isoxicam.
KanamycinTenoxicam may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Kebuzone.
KetoconazoleThe metabolism of Tenoxicam can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tenoxicam.
LabetalolTenoxicam may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Leflunomide.
LepirudinTenoxicam may increase the anticoagulant activities of Lepirudin.
LevobunololTenoxicam may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tenoxicam.
LithiumThe serum concentration of Lithium can be increased when it is combined with Tenoxicam.
LornoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tenoxicam.
LovastatinThe metabolism of Tenoxicam can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tenoxicam.
LumacaftorThe serum concentration of Tenoxicam can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tenoxicam.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meloxicam.
MesalazineTenoxicam may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tenoxicam.
MetamizoleThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tenoxicam.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenoxicam.
MetipranololTenoxicam may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam.
MetoprololTenoxicam may decrease the antihypertensive activities of Metoprolol.
MetrizamideTenoxicam may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Tenoxicam can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tenoxicam.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tenoxicam.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tenoxicam.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tenoxicam.
NadololTenoxicam may decrease the antihypertensive activities of Nadolol.
NadroparinTenoxicam may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Tenoxicam is combined with NCX 4016.
NeomycinTenoxicam may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nepafenac.
NetilmicinTenoxicam may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Tenoxicam can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tenoxicam.
OlopatadineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Olopatadine.
OlsalazineTenoxicam may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenoxicam.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tenoxicam.
OmeprazoleThe metabolism of Tenoxicam can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Orgotein.
OtamixabanTenoxicam may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxaprozin.
OxprenololTenoxicam may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Parecoxib.
ParomomycinTenoxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololTenoxicam may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateTenoxicam may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tenoxicam.
PhenindioneTenoxicam may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Tenoxicam can be increased when combined with Phenobarbital.
PhenprocoumonTenoxicam may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Phenylbutazone.
PhenytoinThe metabolism of Tenoxicam can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenoxicam.
PindololTenoxicam may decrease the antihypertensive activities of Pindolol.
PiretanideTenoxicam may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Piroxicam.
PlicamycinTenoxicam may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tenoxicam.
PractololTenoxicam may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tenoxicam.
PrimidoneThe metabolism of Tenoxicam can be increased when combined with Primidone.
ProbenecidThe serum concentration of Tenoxicam can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Propacetamol.
PropranololTenoxicam may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tenoxicam.
Protein CTenoxicam may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTenoxicam may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Tenoxicam is combined with PTC299.
PuromycinTenoxicam may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Tenoxicam can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tenoxicam.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tenoxicam.
QuinineThe metabolism of Tenoxicam can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tenoxicam.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tenoxicam.
ResveratrolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol.
ReviparinTenoxicam may increase the anticoagulant activities of Reviparin.
RibostamycinTenoxicam may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Tenoxicam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Tenoxicam can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Risedronate.
RivaroxabanTenoxicam may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Rofecoxib.
SalicylamideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tenoxicam.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tenoxicam.
SecobarbitalThe metabolism of Tenoxicam can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Seratrodast.
SildenafilThe metabolism of Tenoxicam can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Tenoxicam can be decreased when combined with Sorafenib.
SotalolTenoxicam may decrease the antihypertensive activities of Sotalol.
SpectinomycinTenoxicam may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tenoxicam.
SpironolactoneTenoxicam may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Tenoxicam is combined with SRT501.
StreptomycinTenoxicam may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinTenoxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Tenoxicam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Tenoxicam can be decreased when combined with Sulfamethoxazole.
SulfasalazineTenoxicam may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tenoxicam.
SulfisoxazoleThe metabolism of Tenoxicam can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Sulindac.
SulodexideTenoxicam may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Suprofen.
TacrolimusTenoxicam may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tenoxicam.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tenoxicam.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tenoxicam.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tenoxicam.
TenofovirThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tenofovir.
TepoxalinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Tenoxicam can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Tenoxicam can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tiludronate.
TimololTenoxicam may decrease the antihypertensive activities of Timolol.
TobramycinTenoxicam may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Tenoxicam can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolmetin.
TorasemideTenoxicam may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tenoxicam.
TranilastThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tenoxicam.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tenoxicam.
TriamtereneTenoxicam may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tenoxicam.
TrimethoprimThe metabolism of Tenoxicam can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Valdecoxib.
Valproic AcidThe metabolism of Tenoxicam can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tenoxicam.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tenoxicam.
VoriconazoleThe metabolism of Tenoxicam can be decreased when combined with Voriconazole.
WarfarinTenoxicam may increase the anticoagulant activities of Warfarin.
XimelagatranTenoxicam may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Tenoxicam can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Indian J Biochem Biophys. 2001 Feb-Apr;38(1-2):56-63. [PubMed:11563332 ]
  2. Yamada M, Niki H, Yamashita M, Mue S, Ohuchi K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharmacol Exp Ther. 1997 May;281(2):1005-12. [PubMed:9152412 ]
  3. Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H: In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43. [PubMed:15943176 ]
  4. Yilmaz H, Gurel S, Ozdemir O: The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42. [PubMed:16245223 ]
  5. Galvao RI, Diogenes JP, Maia GC, Filho EA, Vasconcelos SM, de Menezes DB, Cunha GM, Viana GS: Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res. 2005 Jan;30(1):39-46. [PubMed:15756931 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Yamada M, Niki H, Yamashita M, Mue S, Ohuchi K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharmacol Exp Ther. 1997 May;281(2):1005-12. [PubMed:9152412 ]
  2. Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H: In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43. [PubMed:15943176 ]
  3. Lucio M, Ferreira H, Lima JL, Reis S: Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity. Med Chem. 2006 Sep;2(5):447-56. [PubMed:17017983 ]
  4. Lora M, Morisset S, Menard HA, Leduc R, de Brum-Fernandes AJ: Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids. 1997 May;56(5):361-7. [PubMed:9175172 ]
  5. Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Indian J Biochem Biophys. 2001 Feb-Apr;38(1-2):56-63. [PubMed:11563332 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23